Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Alcon Japan Aims to Be Leader in Glaucoma Treatment: President Kodama
October 14, 2002
-
ARCHIVE OTC NEWS IN BRIEF
October 14, 2002
-
ARCHIVE Korosho to Take Action to Materialize Industry Vision
October 14, 2002
-
ARCHIVE Yamanouchi Aims at \570 Bil. Sales in FY2004: President Takenaka
October 14, 2002
-
ARCHIVE Korosho Plan for Healthcare Reform to Be Presented by End of November
October 14, 2002
-
ARCHIVE Healthcare Expenditures Down 1.6% in 2nd QTR VS 1st QTR
October 14, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
October 14, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 14, 2002
-
ARCHIVE Physician-led Trials to Start on New Indication for Irinotecan
October 14, 2002
-
ARCHIVE Korosho Pledges to Smoothly Implement New Blood Law
October 14, 2002
-
ARCHIVE Korosho to Give Priority to Useful Drugs in Clinical Trial Consultation
October 14, 2002
-
ARCHIVE New ADR Information System under Investigation
October 14, 2002
-
COMMENTARY BARKER ON DRUGS (9)
October 14, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
October 14, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
October 14, 2002
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
October 14, 2002
-
ARCHIVE New Chugai Aims to Obtain 5% Market Share in 2005: President Nagayama
October 14, 2002
-
ARCHIVE Denka Seiken to Develop Tissue Culture Influenza Vaccines
October 14, 2002
-
ARCHIVE Suzuken Ends Acquisition of Ohmori to Regain the Top Position
October 14, 2002
-
ARCHIVE MPRF Invites Applications for Research Grants in Psychiatry
October 14, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…